Understanding the present, shaping the future.

Search
11:12 PM UTC · MONDAY, JUNE 1, 2026 XIANDAI · Xiandai
Jun 1, 2026 · Updated 11:12 PM UTC
Science

Common fitness supplement creatine may slow Alzheimer’s cognitive decline

New clinical research suggests that creatine, a staple in gym bags worldwide, can boost brain energy and slow cognitive decline in early-stage Alzheimer’s patients by 30%.

Lena Kim

2 min read

A growing body of research suggests that creatine—a supplement traditionally marketed to athletes for muscle growth—may offer significant benefits for brain health. According to recent findings reported by thesciverse.org, the supplement helps raise energy levels in neurons, potentially slowing cognitive decline in patients with early Alzheimer’s disease by 30%.

While millions of users currently consume creatine to improve bench press performance or accelerate recovery between sets, most are unaware of its neurological impact. The supplement crosses the blood-brain barrier, where it increases phosphocreatine levels. This process provides an essential energy buffer for brain cells, which are the most energy-demanding in the human body.

Although the brain represents only 2% of total body mass, it consumes roughly 20% of the body’s energy. Neurons rely on adenosine triphosphate (ATP) to maintain cellular processes and release neurotransmitters. When brain creatine levels are sufficient, this system acts as a rapid-response mechanism, regenerating ATP during periods of high mental demand, such as problem-solving or memory encoding.

The bioenergetic crisis in aging brains

The link between creatine and neurodegeneration centers on a phenomenon researchers call a "bioenergetic crisis." Data published in theJournal of Psychiatry and Brain ScienceandAlzheimer’s and Dementia: Translational Research and Clinical Interventionsindicate that as the brain ages, its ability to produce energy falters. In patients with Alzheimer’s, phosphocreatine levels and the activity of the enzyme creatine kinase are significantly lower than in healthy individuals.

This deficiency leaves neurons chronically energy-deprived. Because the creatine system can facilitate ATP production through pathways that do not rely on fully functional mitochondria, it has emerged as a promising therapeutic target.

The University of Kansas Medical Center’s recent "Creatine to Augment Bioenergetics in Alzheimer’s" (CABA) trial provided the first clinical look at this potential. By supplementing with creatine, researchers aim to restore the energy balance in neurons that are struggling to maintain normal synaptic function.

Despite the significant clinical potential, the outlet reported that these cognitive benefits remain largely absent from the marketing materials found on commercial creatine products. The findings suggest that the supplement’s utility extends far beyond the gym, offering a potential lifeline for maintaining cognitive performance in healthy adults and those facing neurodegenerative conditions.

Comments